32,073 Shares in Lantheus Holdings, Inc. $LNTH Acquired by Expect Equity LLC

Posted by Geri Gentry on Aug 26th, 2026

Expect Equity LLC acquired a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH – Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 32,073 shares of the medical equipment provider’s stock, valued at approximately $3,558,000. Lantheus comprises approximately 2.3% of Expect Equity LLC’s portfolio, making the stock its 11th largest position.

Several other hedge funds also recently bought and sold shares of the stock. Western Wealth Management LLC purchased a new stake in Lantheus in the 1st quarter worth approximately $25,000. Smartleaf Asset Management LLC grew its position in Lantheus by 63.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock valued at $34,000 after acquiring an additional 197 shares in the last quarter. Parallel Advisors LLC grew its stake in shares of Lantheus by 122.6% during the fourth quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock valued at $36,000 after acquiring an additional 298 shares in the last quarter. Osterweis Capital Management Inc. acquired a new stake in Lantheus during the 2nd quarter valued at approximately $36,000. Finally, Bessemer Group Inc. increased its stake in shares of Lantheus by 221.2% in the first quarter. Bessemer Group Inc. now owns 514 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 354 shares during the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Wall Street Analysts Forecast Growth

LNTH has been the subject of a number of research analyst reports. Leerink Partners set a $102.50 price target on Lantheus in a report on Monday, August 3rd. Wall Street Zen lowered shares of Lantheus from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. William Blair set a $102.50 price target on Lantheus in a report on Monday, August 3rd. The Goldman Sachs Group reiterated a “neutral” rating and set a $94.00 price objective on shares of Lantheus in a research note on Thursday, May 7th. Finally, Weiss Ratings cut shares of Lantheus from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, August 13th. Four research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $108.11.

View Our Latest Research Report on LNTH

Lantheus Stock Up 0.1%

LNTH opened at $100.87 on Wednesday. The company has a debt-to-equity ratio of 0.43, a current ratio of 3.06 and a quick ratio of 2.89. The company has a market capitalization of $6.58 billion, a PE ratio of 24.36 and a beta of -0.03. The business has a 50-day moving average of $103.92 and a 200-day moving average of $91.01. Lantheus Holdings, Inc. has a fifty-two week low of $49.67 and a fifty-two week high of $111.86.

Lantheus (NASDAQ:LNTH – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share for the quarter, beating analysts’ consensus estimates of $1.30 by $0.25. Lantheus had a net margin of 17.69% and a return on equity of 28.10%. The business had revenue of $388.18 million for the quarter, compared to the consensus estimate of $363.23 million. During the same quarter last year, the firm earned $1.57 EPS. Lantheus’s revenue for the quarter was up 2.7% on a year-over-year basis. Equities research analysts forecast that Lantheus Holdings, Inc. will post 4.48 EPS for the current fiscal year.

Lantheus Company Profile

(Free Report)

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.